Elekta (EKTA_B) Posts Phase 2 Data Supporting Gamma Knife Cognitive Outcomes

Elekta announced phase 2 data from Sunnybrook showing favorable memory performance 2 months after Leksell Gamma Knife radiosurgery in patients with 5—50 brain metastases, with no difference in time to meaningful cognitive decline between 21—50 vs 5—20 lesions.Material DetailsContext by AI AnalystTh…